Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cemiplimab vs Placebo After Surgery and Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma
jRCT2080224968Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in cutaneous squamous cell carcinoma (cSCC) comparing Cemiplimab arm with Placebo arm (2 arms). Started Nov 2019; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on jRCT2080224968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224968.